碳酸氢钠林格液用于失血性休克:与其他晶体液比较的Meta分析
本Meta分析检索Cochrane、EMBASE、MEDLINE和PubMed数据库,纳入3项研究,比较碳酸氢钠林格液(BRS)与其他晶体液在创伤性失血性休克(THS)中的疗效、死亡率、血流动力学效应和不良结局。结果显示,BRS组生存率OR为1.86(95%CI:0.94,3.71;p=0.08;I²=0%),总不良事件OR为0.14(95%CI:0.06,0.35;p<0.0001;I²=22%),心率平均差为-4.49(95%CI:-7.55,-1.44;p=0.004;I²=13%),平均动脉压平均差为2.31(95%CI:-0.85,5.47;p=0.15;I²=66%)。结论认为,BRS可显著减少并发症,包括ARDS、MODS和总不良事件,并显著降低心率;BRS可能有助于器官稳定和潜在生存改善。
要点
- 与其它晶体液相比,BRS组总不良事件OR为0.14(95%CI:0.06,0.35;p<0.0001;I²=22%),显著减少。
- BRS组ARDS和MODS等并发症显著减少(原文结论,未给出具体数值)。
- BRS组心率平均差为-4.49(95%CI:-7.55,-1.44;p=0.004;I²=13%),显著降低。
- BRS组生存率OR为1.86(95%CI:0.94,3.71;p=0.08;I²=0%),未达统计学显著。
- BRS组平均动脉压平均差为2.31(95%CI:-0.85,5.47;p=0.15;I²=66%),未达统计学显著。
适用人群与场景
- 创伤性失血性休克(THS)患者。
研究设计与关键结果
- 研究类型:Meta分析,纳入3项研究,检索Cochrane、EMBASE、MEDLINE和PubMed数据库。
- 主要结局:与其它晶体液相比,BRS组生存率OR为1.86(95%CI:0.94,3.71;p=0.08;I²=0%)。
- 总不良事件:BRS组OR为0.14(95%CI:0.06,0.35;p<0.0001;I²=22%)。
- 心率平均差:-4.49(95%CI:-7.55,-1.44;p=0.004;I²=13%),BRS组较低。
- 平均动脉压平均差:2.31(95%CI:-0.85,5.47;p=0.15;I²=66%)。
- 结论:BRS组ARDS、MODS和总不良事件显著减少,心率显著降低。
证据类型、等级与局限
- 证据类型:Meta分析(纳入3项研究)。
- 异质性:生存率I²=0%,总不良事件I²=22%,心率I²=13%,平均动脉压I²=66%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于创伤性失血性休克患者,与其它晶体液相比,使用BRS可能减少总不良事件、ARDS和MODS,并降低心率。
- BRS对生存率和平均动脉压的影响未达统计学显著。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The choice of fluid resuscitation in Traumatic Hemorrhagic shock (THS) remains a critical aspect of patient management. Bicarbonated Ringers solution (BRS) has shown promise due to its composition resembling human Extracellular Fluid and its potential benefits on hemodynamics.
OBJECTIVE: To evaluate the efficacy, mortality rates, hemodynamic effects, and adverse outcomes of Sodium Bicarbonate Ringer's Solution in the treatment of hemorrhagic shock, as compared to other relevant interventions.
METHOD: A comprehensive examination of the available literature was performed by conducting systematic searches in prominent databases such as Cochrane, EMBASE, MEDLINE, and PubMed. The process employed predefined criteria to extract relevant data and evaluate the quality of the studies. The outcome measures considered encompassed survival rates, mortality, mean arterial pressure (MAP), heart rate (HR), and adverse events.
RESULT: The meta-analysis of three studies showed that compared to the other crystalloids, the use of BRS had an odds ratio for survival of 1.86 (95% CI: 0.94, 3.71; p = 0.08; I2 = 0%), an odds ratio for total adverse events of 0.14 (95% CI: 0.06, 0.35; p < 0.0001; I2 = 22%), a mean difference in heart rate of -4.49 (95% CI: -7.55, -1.44; p = 0.004; I2 = 13%), and a mean difference in mean arterial pressure of 2.31 (95% CI: -0.85, 5.47; p = 0.15; I2 = 66%).
CONCLUSION: BRS demonstrated a significant reduction in complications, including adult respiratory distress syndrome (ARDS), Multiple Organ Dysfunction (MODS), and Total Adverse Effects, when compared to other solutions in the treatment of THS. Additionally, THS patients resuscitated with BRS experienced a notable decrease in heart rate. The findings suggest BRS may contribute to organ stability and potential survival improvement due to its similarity to human Extracellular Fluid and minimal impact on the liver.
参考来源
- Shafique MA, Shaikh NA, Haseeb A, et al. Sodium bicarbonate Ringer's solution for hemorrhagic shock: A meta-analysis comparing crystalloid solutions. Am J Emerg Med. 2023. PMID: 37988980. doi:10.1016/j.ajem.2023.11.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。